E-ISSN 2602-4837
The effects of hyperbaric oxygen therapy on an experimental cisplatin-induced ototoxicity model [Tr-ENT]
Tr-ENT. 2020; 30(2): 46-51 | DOI: 10.5606/Tr-ENT.2020.62681

The effects of hyperbaric oxygen therapy on an experimental cisplatin-induced ototoxicity model

Burak Dikmen1, Hakan Avcı1, Şaban Çelebi2
1Department of Otorhinolaryngology, University of Health Sciences, Kartal Dr. Lütfi Kırdar Training and Research Hospital, Istanbul, Turkey
2Private Practice, Ear, Nose and Throat Diseases, Istanbul, Turkey

INTRODUCTION: This study aims to investigate the protective effect of hyperbaric oxygen therapy (HBOT) as an antioxidant agent on cisplatin ototoxicity.
METHODS: Between June 4th, 2014 and June 13th, 2014, a total of 15 adult female Wistar albino rats were used in this study. The rats were divided into the following groups: Group A comprised of five rats and had prophylactic one course of HBOT before intraperitoneal (IP) cisplatin injection, followed by two more courses of HBOT. Group B comprised of five rats receiving three cycles of HBOT after 10 mg/kg of IP cisplatin administration. Group C served as the control group, including five rats, and received 10 mg/kg IP cisplatin without any additional treatment. The distortion product otoacoustic emission amplitudes of the rats were obtained before and after the study.
RESULTS: Group A and Group C showed a significant decrease in all measurements (4,004 Hz, 4,761 Hz, 5,188 Hz, 5,652 Hz, 6,726 Hz, and 7,996 Hz) after cisplatin administration compared to that of baseline measurement. In Group B, a significant decrease was observed in the majority of the measurements, although no significant difference was found in 4,761 Hz.
DISCUSSION AND CONCLUSION: Our study results suggest that HBOT neither provides a protective nor therapeutic effect in a rat cisplatin-ototoxicity model.

Keywords: Cisplatin ototoxicity, distortion product otoacoustic emission, hearing loss, hyperbaric oxygen

Burak Dikmen, Hakan Avcı, Şaban Çelebi. The effects of hyperbaric oxygen therapy on an experimental cisplatin-induced ototoxicity model. Tr-ENT. 2020; 30(2): 46-51

Corresponding Author: Hakan Avcı, Türkiye
LookUs & Online Makale